Publications & Case Studies
TABLE OF CONTENTS

*Journal of Therapy and Management in HIV Infection, 2013, 1, 40-44*

II. Plasma Solutions Case Study: “Treatment of Proximal Hamstring Syndrome”

III. Plasma Solutions Case Study: “Dermal Micro Grafting with Platelet Rich Plasma and Fibrin Matrix to Treat Diabetic Ulcerations”
Case Study: Novel Approach to HIV-Associated Neuropathy
Platelet Rich Plasma Successful in Treating HIV-Associated Peripheral Neuropathy

James Hays1,*, John O'Neil Simmonds1, Wilbert Jordan2 and Nathan Lucas1

1PlasmaGenix, Inc. 455 North Prairie Ave, Inglewood, CA 90301, USA
2OASIS Clinic, Martin Luther King, Jr. Harbor Hospital, Charles R. Drew University, 1807 E. 120th St., Los Angeles, CA 90059, USA

Abstract: Distal symmetrical peripheral neuropathy (DSPN) is the most common neurologic complication of Human Immunodeficiency Virus (HIV) infection. DSPN is a distressing pain syndrome and infected patients have limited treatment options for alleviating symptoms. Platelet Rich Plasma has been found to be effective in relieving pain associated with chronic and acute musculoskeletal conditions as well as arthritic conditions. We tested the hypothesis that platelet rich plasma alleviates symptoms of HIV-associated DSPN. A 50-year-old African American patient was referred for long-standing bilateral leg neuropathy. The patient was treated with an injection of platelet rich plasma therapy every two weeks for 12 weeks. The treatment outcomes were pain intensity, pain relief, sensory perception, quality of life, mood, and function. After the first therapeutic injection of platelet rich plasma, the patient reported significant improvement in pain relief, sensory perception, and range of motion. The therapy was effective in relieving pain so the patient discontinued use all other pain medications including Vicodin and Neurontin.

This case report provides evidence that platelet rich plasma is effective in relieving painful numbness, tingling and burning related to HIV-associated DSPN. Platelet rich plasma may be a valuable option for treatment of symptoms associated with DSPN among HIV patients.

Keywords: Distal symmetrical peripheral neuropathy, H.I.V. neuropathy, neurogenic growth factors, platelet-rich-plasma, nerve pain.

INTRODUCTION

Distal Symmetrical Peripheral Neuropathy (DSPN) is the most common neurologic complication of HIV infection. DSPN can be categorized as Primary HIV-associated DSPN or Antiretroviral Therapy Toxic Neuropathy (ATN) [1,2] which has increased in frequency with the advent of this class of medications. DSPN affects approximately 57% of HIV patients [1] and is characterized by painful numbness, muscle weakness, depressed reflexes and impaired temperature homeostasis. Treatments options for temporary symptomatic relief include Memantine [3], Peptide-T, Amitriptyline, Gabapentin, topical Capsaicin 8%, recombinant human growth factor, and smoked cannabis [4]. However, the results of clinical trials indicate few are efficacious and most are financially burdensome to patients [5-7]. Therefore, there is an urgent need for adequate and affordable therapeutic options for DSPN.

Increasing evidence supports the hypothesis that platelet rich plasma may reduce neuropathic pain by triggering the cascade of events that occur in wound repair [8-10]. Platelet enriched plasma contains a high concentration of platelets, clotting factors and growth factors [11,12]. These growth factors, released by platelets, help to facilitate wound repair. In this research, we propose to test the hypothesis that platelet rich plasma alleviates symptoms of HIV-associated DSPN in a case report.

CASE PRESENTATION

A 50-year-old African American female presented to a PlasmaGenix affiliated clinic after being referred by her HIV specialist, for evaluation and possible treatment of her neuropathy. She presented with a chief complaint of bilateral foot and leg pain, numbness, tingling, and burning sensation which persisted for 15 years. She also reports that her symptoms are more pronounced on the left lower extremity. The patient also stated that she has difficulty walking for extended periods of time and has been in a state of constant and severe pain since her symptoms began. She rated the pain as an 8 out of 10 on the pain scale. The medications the patient was taking for pain include Vicodin, Neurontin, Lyrica, Capsaicin and Fentanyl patch but has not experienced symptomatic relief.

The symptoms have significantly decreased her quality of life. The patient is distressed and depressed by her situation since she used to be physically active
prior to the DSPN. DSPN was diagnosed in the patient based on the Semmes Weinstein monofilament examination. A 5.07mm S-W monofilament was placed perpendicular to the following areas with enough pressure to cause the nylon filament to bend in the shape of the letter “C”: The plantar metatarsal 1, 3 and 5 areas as well as the plantar skin of the great toe. The monofilament was held in place for approximately 1 second. The patient was unable to sense the monofilament on the plantar great toe area as well as the plantar 5th metatarsal area bilaterally. Additionally, further neurologic testing was performed using a 128-Hz tuning fork. After causing the tuning fork to vibrate, the base of the tuning fork was placed at the medial and lateral malleolus as well as the first metatarsal phalangeal joint areas bilaterally. The patient showed diminished vibration sensitivity particularly at the medial malleoli bilaterally.

She was diagnosed with HIV in 1985 and her HIV has been well managed. Her CD4 count at the time of her visit was over 500 cells/mm3 and she was not on anti-retroviral therapy. The patient's past medical history included type 2 diabetes mellitus and left leg liposarcoma for which she underwent partial quadriceps resection and radiation. Because of the liposarcoma, she has developed a left-sided limp and has become sedentary. The patient's hemoglobin A1c was 7.5% at the time of treatment and her diabetes was managed with Humalog 100 units and Lantus 100 units. The patient was on no other medications at the time of treatment.

During the physical exam, she appeared her stated age and her vitals were within normal limits. During the neurological exam, she was alert and oriented and her speech was clear and fluent. Her cranial nerves were grossly intact. No pronator drift was noted, motor strength was 5/5 for upper extremities and 4/5 for lower extremities with greater strength in the right lower extremity than the left. Posture was normal but her ability to stand was limited. Gait was limited to small to medium steps and the patient had a left-sided limp. Light touch, pinprick, position sense, monofilament testing, and vibration sense were diminished in the lower extremities.

Patellar and Achilles reflexes were hypoactive and elicited with reinforcement. The following pulses were present: Dorsalis Pedis: 1+ Bilaterally, Posterior Tibial: 1+ Bilaterally. Skin was cool to the touch in the lower extremities and no digital or leg hair was present. Additionally, the skin was mildly atrophic and non-elastic. There were no evidence of ulcerations or fissures.

**PROTOCOL AND MANAGEMENT**

The patient was provided with detailed information about the procedure including potential risks and complications such as swelling and pain at the injection sites. After written informed consent was obtained, the injection sites were prepped using 65% alcohol. Using a butterfly blood collection set with a 21gauge needle, approximately 20MLs of whole blood were collected in 2-10 ML test tubes. Utilizing an adaptation from a published platelet processing protocol [13], each tube was then deposited into the centrifuge (Figure 1). The centrifuge was then set for 10 minutes at 3600 RPM. After the centrifuge process was complete, both platelet rich and platelet poor plasma were extracted from each test tube and combined with .5MLs of a proprietary mixture of a platelet aggregator and platelet activator yielding approximately 10 ML’s of the combined mixture. This mixture was then placed into a 10 ML syringe with a 27gauge needle. The injection sites were identified below the knee along the L4 and L5 skin dermatomes bilaterally. Approximately three 2 ML injections were administered along the L4 dermatomes and two 2 ML injections along the L5 skin dermatomes bilaterally. Each injection site was massaged thoroughly in effort to disperse the neurogenic growth factors evenly. The injection site were covered with bandages and the patient was monitored for approximately 10 minutes before being discharged and given post therapeutic materials and follow-up appointment for two weeks.

**TREATMENT OUTCOMES**

Treatment outcomes were measured using the *PlasmaGenix Treatment Efficacy Treatment Scale* (Table 1) for 12 weeks and the following variables were followed and recorded throughout treatment:

1. Pain intensity: 1-10 (10 being the worst pain)
2. Pain relief: None, Moderate, Significant.
4. Quality of life: According to the Karnofsky performance status scale [14].
5. Mood: 1-10 (10 being the worst mood)
6. Function: flexibility, standing longevity, walking distance being characterized as diminished, improved or same.

Within the first 2 weeks of treatment, the patient reported moderate relief of her pain and an improvement in flexibility and ability to walk. Within 4 weeks, the patient reported significant relief of her pain and improved function. Within 6 weeks, the patient reported significant relief of her pain and improved function, quality of life and mood.

Within 6 weeks, the patient reported significant relief of her pain and improved function, quality of life and mood. Additionally sensory perception was found to be improved on medical exam and minimal hair growth was appreciated. These observations are documented.

Three months (12 weeks) after the first injection, the patient reported to not be limping anymore, being able to bend her left leg (which she had not been able to do for over 10 years), and able to sit cross-legged. She is now able to walk up a flight of stairs with more ease due to increased mobility and hopes to be able to go hiking again in the near future.

DISCUSSION

In this investigation, we report the case study of a patient whose symptoms were completely relieved following a proprietary new protocol and treatment plan based on the regenerative properties of Activated Autologous Platelet Rich Platelet Poor Plasma (AAPRPP).

Several studies have demonstrated the positive effect of platelet rich plasma when administered in humans. Evidence which supports efficacy of platelet rich plasma includes case studies [15,16], cohort studies [17,18,19], and a randomized controlled trial [20].
The randomized controlled trial conducted in the United States evaluated the role of platelet rich plasma as a treatment for diabetic foot ulcers [21]. Study participants included diabetes patients between the ages of 18 and 95 years suffering from an ulcer. 72 patients were randomized to receive standard of care with platelet rich plasma gel or saline gel. During a 12 week period, wounds healed in 68.4% of the platelet rich plasma group compared to 42.9% of the saline gel group. Furthermore, patients healed wounds in the platelet rich plasma group by a mean of 4.5 days less than the saline gel group.

The randomized controlled trial conducted in the United States evaluated the role of platelet rich plasma as a treatment for diabetic foot ulcers [21]. Study participants included diabetes patients between the ages of 18 and 95 years suffering from an ulcer. 72 patients were randomized to receive standard of care with platelet rich plasma gel or saline gel. During a 12 week period, wounds healed in 68.4% of the platelet rich plasma group compared to 42.9% of the saline gel group. Furthermore, patients healed wounds in the platelet rich plasma group by a mean of 4.5 days less than the saline gel group.

The benefits of recombinant nerve growth factor in neuropathy have been shown previously. This study shows the benefits of autologous growth factors derived from activated platelets [22, 23]. A clinical trial would be beneficial to measure the possible mechanism of action of platelet rich plasma on peripheral nerves. Neurogenic growth factors may be released during the activation phase of the platelet rich plasma preparation. Additionally, quantitative studies such as nerve conduction studies and skin biopsies to measure peripheral nerve density may be helpful in identifying ways to provide interventions to prevent peripheral neuropathy development in HIV patients. This method would offer a valuable alternative to current and ineffective treatment options. Important advantages are that this method of treatment is easy to use, has point of care administration, and relatively quick and painless application which facilitates compliance. Another inherent advantage is that AAPRPP is derived from the patient's own blood, reducing the risk of allergic or adverse reactions other than minimal injection site tenderness.

In summary, platelet rich plasma may act directly on neurons to promote axon regeneration thereby alleviating neuropathic pain. The present research provides evidence that platelet rich plasma may be used to treat HIV-associated neuropathy which adds new data to the extant literature on this topic.

REFERENCES


http://dx.doi.org/10.1371/journal.pone.0014433

http://dx.doi.org/10.1185/03007995.2013.781019


http://dx.doi.org/10.1016/j.injury.2008.06.025

http://dx.doi.org/10.1097/BOT.0b013e3181317e793f

http://dx.doi.org/10.1080/08977190600821327

http://dx.doi.org/10.1097/PHM.0b013e3181f1c7ef


http://dx.doi.org/10.1097/00129334-200609000-00010

http://dx.doi.org/10.1016/j.bips.2008.04.048

http://dx.doi.org/10.2337/diacare.24.3.483

http://dx.doi.org/10.1016/j.transci.2004.01.004

http://dx.doi.org/10.1111/j.1524-475X.2008.00426.x

http://dx.doi.org/10.1055/s-2002-19824


http://dx.doi.org/10.1212/WNL.57.7.1313

http://dx.doi.org/10.1212/WNL.54.5.1080

Received on 31-10-2013 Accepted on 11-11-2013 Published on 10-01-2014

DOI: http://dx.doi.org/10.12970/2309-0529.2013.01.02.2

© 2013 Hays et al.; Licensee Synergy Publishers. This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ABOUT
PROXIMAL HAMSTRING SYNDROME

The hamstrings are an essential muscle group in running. They flex your knee and assist in hip extension, meaning they are active at multiple points in your gait cycle. While the most common hamstring injuries are acute or chronic muscle strains, they are also vulnerable to tendinitis at their origin, an injury termed high hamstring tendinopathy or proximal hamstring tendinitis.

While rare, this injury is difficult to treat and can become a prolonged and chronic problem. The relatively limited scientific and medical reports extant are fairly recent, and as such, there are no solid numbers on what percentage of runners come down with it.

The hamstrings run from the top of your tibia, just behind your knee, up along the back side of your thigh and towards your pelvis. While one branch of the hamstrings attaches to the femur, the rest course up your thigh and underneath your glute muscles, attaching to the pelvis at a bony prominence called the ischial tuberosity.

These twin “peaks” of bone are sometimes referred to as your “sitting bones,” as they support much of your weight while sitting, especially on hard surfaces. The junction between the tendons of the hamstrings and the ischial tuberosity is the area affected by high hamstring tendinopathy.

Sufferers will complain of pain local to the ischial tuberosity when running, especially when accelerating and sustained faster paced running. The pain will most likely be an intense ache in nature, rather than sharp or stabbing. Due to the anatomical proximity to the common hamstring origin, the sciatic nerve can sometimes be affected, which can cause referred pain into the posterior thigh. Once aggravated, sitting on solid surfaces can also be uncomfortable, as can direct palpation and pressing onto the ischial tuberosity manually.

CASE STUDY

The purpose of this case study is to explain and showcase a novel approach to treat and cure proximal hamstring syndrome with autologous blood therapy.

A 38 year old female was referred to the Plasmagenix Medical Corporation for an evaluation and treatment for chronic proximal hamstring syndrome. Prior to referral, the patient was diagnosis with chronic proximal hamstring syndrome via objective evidence on MRI and her clinical presentation. The patient’s subjective and objective findings demonstrated a Nirschl Phase Rating of 4 (Table 1). The patient was treated with 4-5 months of intense physical therapy and one cortisone injection with no improvement. The patient was evaluated by a Certified Plasmagenix Medical Provider and was indicated for treatment with autologous blood therapy. After informed consent a Right arm tourniquet was applied and the targeted vein identified. The area was then prepped in the usual aseptic manner. Using a butterfly blood collection set with a 21 gauge needle, approximately 18 mL of whole blood was collected from the patient. Approximately 12 mL of whole blood was deposited into the centrifuge container under sterile technique. The centrifuge was counterbalanced with 18 mL of normal saline in a similar container.
The centrifuge was then set at 10 minutes at 3600 RPM. After 10 minutes had elapsed, a thin buffy coat layer representing platelet rich plasma could be identified in the centrifuge tube. Using the plasma extractor, all plasma was removed down to the layer of platelet rich plasma. Using a 12 mL syringe approximately 12 mL of platelet rich plasma was extracted from the centrifuge tube.

The platelet rich plasma was then taken into the examination room. The patient was placed in the prone position on the treatment table. The skin over and surrounding the treatment area was cleaned with Betadine. The area was covered with sterile drapes, leaving a small window opening for needle placement. Ultrasound was used to identify the bony landmarks of the right ischial tuberosity and the planned needle approach. The skin, subcutaneous tissue, and muscle within the planned needle approach were anesthetized with 1% Lidocaine. All injected medications were preservative free. With ultrasound guidance an 18 gauge needle introduced to the Right biceps femoris, semimembranosus, and semitendinosus tendons. Percutaneous needle tenotomy was performed by way of multiple fenestrations to the Right biceps femoris, semimembranosus, and semitendinosus tendons. Finally, the treatment solution, consisting of 6 cc of platelet rich plasma and platelet poor plasma activated with Plasmagenin’s proprietary compound was injected in the Right biceps femoris, semimembranosus, and semitendinosus tendons. All injected medications were preservative free. Sterile technique was used throughout the procedure.

This patient underwent two therapeutic procedures two weeks apart with concurrent physical therapy treatment. The patient was re-evaluated two months after the commencement of her treatment, and presented pain-free with all physical activities.

Table 1

<table>
<thead>
<tr>
<th>Phase</th>
<th>Level of Disability</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Mild stiffness or soreness after activity with resolution of symptoms within 24 hours.</td>
</tr>
<tr>
<td>2</td>
<td>Mild stiffness or soreness prior to activity that is relieved by warm-up; symptoms are not present during activity but return afterward and resolve within 48 hours.</td>
</tr>
<tr>
<td>3</td>
<td>Pain that is present during activity without causing activity modification.</td>
</tr>
<tr>
<td>4</td>
<td>Pain with activity that causes modification.</td>
</tr>
<tr>
<td>5</td>
<td>Pain that is present during all activities and occurs with activities of daily living.</td>
</tr>
<tr>
<td>6</td>
<td>Intermittent rest pain that does not disturb sleep.</td>
</tr>
<tr>
<td>7</td>
<td>Constant rest pain that disturbs sleep.</td>
</tr>
</tbody>
</table>

Adapted from Caccio et al. and Nirschl and Ashman.13
ABOUT DIABETIC WOUNDS

A diabetic foot ulcer is an open sore or wound that occurs in approximately 15 percent of patients with diabetes and is commonly located on the bottom of the foot. Of those who develop a foot ulcer, 6 percent will be hospitalized due to infection or other ulcer-related complications.

Diabetes is the leading cause of non-traumatic lower extremity amputations in the United States, and approximately 14-24 percent of patients with diabetes who develop a foot ulcer will require an amputation. Foot ulceration precedes 85 percent of diabetes-related amputations. Research has shown, however, that development of a foot ulcer is preventable.

CAUSES

Anyone who has diabetes can develop a foot ulcer. Native Americans, African Americans, Hispanics, and older men are more likely to develop ulcers. People who use insulin are at higher risk of developing a foot ulcer, as are patients with diabetes-related kidney, eye, and heart disease. Being overweight and using alcohol and tobacco also play a role in the development of foot ulcers.

CASE STUDY

The purpose of this case study is to explain and showcase a novel approach to treat diabetic wounds using harvested dermal cells combined with autologous fibrin matrix.

A 58-year-old Hispanic male presented to a PlasmaGenix Affiliated Clinic with a pre-gangrenous right 5th digit that also had a foul-smelling drainage of several days duration that was progressively getting worse. Mild ascending cellulitis involving the dorsal left foot could be appreciated as well. The patient recalled that the condition began after wearing new steel toed boots that were ill-fitting. Pain upon palpation to the anterior aspect of the right leg was observed. The patient’s medical history was remarkable for diabetes as well as hypertension. Random BS at the time of evaluation was documented to be 243. The patient was afebrile.

Physical Examination: The dorsalis pedis arterial pulses were palpable at +1/4 bilaterally. The posterior tibial arteries were non-palpable bilaterally. These sub venous plexus filling time was within normal limits bilaterally and the skin was moist and supple. Digital hair could also be appreciated. The right 5th digit was completely cyanotic with mild to moderate erythema extending from the dorsum of the right foot onto the anterior ankle. The 4th right interdigital space showed ulceration and communication to deeper structures with sinus tracking and undermining suggestive of an aggressive necrotizing infectious process.
Procedure: The right 5th digit was disarticulated under local anesthesia and all necrotic and devitalized tissue was debrided to the level of healthy bleeding tissue. Wound cultures were obtained and were positive for Bacteroides f. and Klebsiella p. The appropriate antibiotics were prescribed based on cultures and sensitivities. The patient was seen every other day for wound dressing and evaluation. After 3 consecutive negative wound cultures, the patient received PlasmaGen with Micro-Dermal grafting.

After informed consent a left arm tourniquet was applied and the targeted vein identified. The area was then prepped in the usual aseptic manner. Using a butterfly blood collection set with a 21 gauge needle, approximately 60 mL of whole blood was collected from the patient. Approximately 19 mL of whole blood was deposited into the centrifuge container under sterile technique. The centrifuge was counterbalanced with 19 mL of normal saline in a similar container. The centrifuge was then set at 10 minutes at 3600 RPM. After 10 minutes had elapsed, a fibrin matrix was identified and extracted from the test tube. After creating a sterile field along with local anesthesia, dermal cells were then harvested from a 2.5cm x 2.5cm area on the contralateral extremity just below the knee.

The harvested cells were pulverized or minced into .8mm pieces and incorporated into the fibrin matrix and applied to the wound bed. An occlusive dressing was applied and remained in tacked for a period of at least 4-5 days. Subsequent treatments included peri-wound injections of PlasmaPro, a high concentration of growth factors and other regenerative proteins.

Fig. C: Dermal cells harvested from the contralateral extremity and micronized into .8mm dermal pieces.

Fig. D: Dermal cells incorporated into platelet rich fibrin matrix.

Fig. E: Dermal micro graft prior to application of occlusive dressing.

Fig. G: Above images show a total of 16 weeks to complete wound closure.